Gamma camera imaging characteristics of 203/212Pb as a theragnostic pair for targeted alpha therapy: a feasibility study
According to our results and first-in-human imaging studies, SPECT/CT imaging with the <sup>203/212</sup>Pb theragnostic pair is clinically feasible. <sup>203</sup>Pb is an appropriate imaging surrogate to investigate pharmacokinetics and perform predictive dosimetry. The less favorable imaging characteristics of <sup>212</sup>Pb make image quantification and post-treatment dosimetry challenging and require further research.
Authors
- David Kästner (ORCID: https://orcid.org/0009-0003-6004-8639)
- Michael K. Schultz (ORCID: https://orcid.org/0000-0002-4554-2212)
- Claudia Brogsitter
- Enrico Michler (ORCID: https://orcid.org/0000-0002-4404-0114)
- Marc Pretze (ORCID: https://orcid.org/0000-0002-6432-5694)
- Robert Freudenberg (ORCID: https://orcid.org/0000-0002-1970-6957)
- Holger Hartmann
- Jörg Kotzerke
Institutions
- Io Therapeutics (United States) (US)
- University Hospital Carl Gustav Carus (DE)
- Technische Universität Dresden (DE)
Publication Details
- Journal
- EJNMMI Physics
- Published
- 2025-05-27
- DOI
- https://doi.org/10.1186/s40658-025-00763-2
- Citations
- 6
- Primary Topic
- Medical Imaging Techniques and Applications
- Type
- article
- Field-Weighted Citation Impact
- 8.16
Funders
- Technische Universität Dresden